Currently Viewing:
Supplements A Managed Care Perspective on Immunotherapy Treatment for Peanut Allergies
Severity of Peanut Allergy and the Unmet Gaps in Care: A Call to Action
Jay A. Lieberman, MD
Management of Peanut Allergy: A Focus on Novel Immunotherapies
Christopher P. Parrish, MD
Currently Reading
The Economic Impact of Peanut Allergies
H. Eric Cannon, PharmD, FAMCP

The Economic Impact of Peanut Allergies

H. Eric Cannon, PharmD, FAMCP
The prevalence of peanut allergies, the most common food allergy in children, has tripled in the past 2 decades. Today, up to 2.5% of the pediatric population has been diagnosed with a peanut allergy. Peanut allergies result in significant medical, out-of-pocket, and opportunity costs to payers, parents, and employers. They are also a leading cause of food allergy–related deaths in children. Although there is evidence that peanut oral immunotherapy may be effective in reducing the severity of the allergy, such approaches require a long intervention with no standardized protocol available. The introduction of biologic compounds to treat peanut allergies has the potential to revolutionize how these patient cases are managed. Their anticipated high cost, however, raises several issues for payers as to how to integrate these new therapies into formularies and treatment continuums.
Am J Manag Care. 2018;24:-S0

Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up